The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on all clinical trials evaluating venetoclax for the investigational treatment of multiple myeloma. Continue reading
Myeloma Patients Europe (MPE) is participating in the Horizon 2020 project, MMPredict, aimed at developing a personalised medicine tool to predict the most effective treatment strategy for individual myeloma patients.
The MMpredict consortium has reached a new milestone in this project by completing the recruitment of the patient samples required in this project. With more than 800 myeloma samples recruited, the project team meets its aimed target population. The current efforts will now be focused on completing the genetic analysis of the obtained study material. During this stage, tumour heterogeneity (i.e. the differences between people’s myeloma) and the patient’s intrinsic characteristics will be investigated. Continue reading
Patient input into medical research is becoming increasingly important. The MPE Advocate Development Programme aims to help myeloma and AL amyloidosis advocates understand the research and development process of drugs, from the preclinical stages through to post-marketing surveillance and national access. Topics include clinical trial design, regulation, pricing and health technology assessment (HTA). The programme combines a series of theoretical sessions delivered by experts with practical sessions that take place during the most important myeloma scientific meetings in Europe such as the European Haematology Association (EHA) Annual Meeting or the European Society of Medical Oncology (ESMO) Annual Meeting. Continue reading
The European Hematology Association (EHA) and European Society for Blood and Marrow Transplantation (EBMT) will hold the first European CAR T Cell Meeting together in Paris on February 14-16, 2019. Continue reading
Myeloma Patients Europe (MPE) is participating in the Horizon 2020 project, MMPredict, aimed to develop a personalised medicine tool to predict the most effective treatment strategy for individual myeloma patients. To explain the main goals of MMPredict, MPE filmed a video with some partners working in the project consortium. Now this video, recorded in English, has been translated into four additional languages: German, Spanish, Dutch and Italian. Continue reading
Initial data from the ongoing phase I clinical trial of bb21217 (CRB-402) were presented at the 60th Annual Meeting of the American Society of Hematology (ASH). This is an investigational next-generation anti-BCMA CAR T cell therapy being studied in patients with relapsed/refractory myeloma. Continue reading
A collaboration between patient advocates and pharmaceutical companies usually requires both parties to sign contracts for different engagements such as for advisory, consultancy, collaborative or speaker engagements. These contracts usually cover areas such as confidentiality, intellectual property, data protection, financial compensation and travel expenses. However, according to the Workgroup of European Cancer Patient Advocacy Networks (WECAN), most of these contracts may be difficult for patient advocates to understand or contain inadequate terms. Aiming to create a simpler legal framework, WECAN is conducting a project coordinated by Myeloma Patients Europe (MPE) in collaboration with Patient Focused Medicines Development (PFMD) and legal experts from 12 pharmaceutical companies. The joint initiative has now released guiding principles for reasonable legal agreements that adequately protect both parties while safeguarding independence and individual interests. Continue reading